Candel Therapeutics

CADLNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$906.745 M

$11.85 +5.71%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$38.2M

Loss-making

Shares outstanding

76,518,565

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#52Attovia TherapeuticsATTO$950.9M
#53SL ScienceSLBT$942.1M
#54Candel TherapeuticsCADL$906.7M
#554D Molecular TherapeuticsFDMT$877.3M
#56Electra TherapeuticsETRA$876.5M

What if Candel Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$395,119.40

Per share 33,343× higher

Bitcoin $1.74T

$22,761.21

Per share 1,921× higher

Nvidia $5.52T

$72,084.04

Per share 6,083× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Candel Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.